Izvorni znanstveni članak
Antibody Profile of Pregnant Women with Antiphospholipid Syndrome and Pregnancy Outcome After Treatment with Low Dose Aspirin and Low-Weight-Molecular Heparin
Marija Glasnović
Ivica Bošnjak
Aleksandar Včev
Ivan Soldo
Maja Košuta
Bahrija Lenz
Elizabeta Glasnović-Horvatić
Silva Soldo-Butković
Nikola Mićunović
Sažetak
The aim of the research was to show our diagnostic and therapeutic experience with antiphospholipid syndrome
(APS) in pregnant women. 36 pregnant women suspect on APS were included in the study: 32 with primary antiphospholipd
syndrome (PAPS) and 4 with secondary antiphospholipid syndrome (SAPS). All pregnant women received
low-molecular-weight-heparin (LMWH) and low dose aspirin (LDA) therapy. Control group represented 26 women with
SAPS and previous bad reproductive anamnesis. Average pregnancy lasted 37.060.707 weeks. LMWH and LDA therapy
was successful in 97.22%. Lupus anticoagulant (LA) was found to be more frequent in PAPS group (71,87%). Anticardiolipin
antibodies (aCL) were found to be more frequent in SAPS (26,66%). For three patients (3.37%), PAPS was diagnosed
due to a fact that they had positive antibeta2-glycoprotein1 (anti-GP1). To make APS diagnosis, it is of great
importance to search for all antiphospholipid antibodies. LMWH and low dose of acetylsalicylic acid should be the first
choice therapy.
Ključne riječi
antiphospholipid syndrome; pregnancy; antibodies
Hrčak ID:
27292
URI
Datum izdavanja:
4.1.2007.
Posjeta: 1.415 *